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When compared with Whites, Black-Americans may have a 40% higher incidence venous thromboembolism
(VTE) incidence. However, whether other VTE characteristics and risk factors vary by race is uncertain. To
compare demographic and baseline characteristics among White- and Black-Americans with VTE, we used
data prospectively collected from consecutive consenting adults enrolled in seven Centers for Disease Con-
trol (CDC) Thrombosis and Hemostasis Centers from August 2003 to March 2009. These characteristics
were compared among Whites (n 5 2002) and Blacks (n 5 395) with objectively diagnosed VTE, both over-
all, and by age and gender. When compared with Whites, Blacks had a significantly higher proportion with
pulmonary embolism (PE), including idiopathic PE among Black women, and a significantly higher propor-
tion of Blacks were women. Blacks had a significantly higher mean BMI and a significantly lower proportion
with recent surgery, trauma or infection, family history of VTE, and documented thrombophilia (solely from
reduced factor V Leiden and prothrombin G20210A prevalence). Conversely, Blacks had a significantly
higher proportion with hypertension, diabetes mellitus, chronic renal disease and dialysis, HIV, and sickle
cell disease. When compared with White women, Black women had a significantly lower proportion with
recent oral contraceptive use or hormone therapy. We conclude that Whites and Blacks differ significantly
regarding demographic and baseline characteristics that may be risk factors for VTE. The prevalence of
transient VTE risk factors and idiopathic VTE among Blacks appears to be lower and higher, respectively,
suggesting that heritability may be important in the etiology of VTE among Black-Americans. Am. J.
Hematol. 85:467–471, 2010. VC 2010 Wiley-Liss, Inc.
Introduction
Most epidemiologic studies of venous thromboembolism
(VTE) risk factors have been conducted within White-Amer-
ican and -European populations [1–4]. However, when
compared with Whites, Black-Americans appear to have a
higher risk for [5,6] and incidence of VTE [7–10]. Two sin-
gle-nucleotide polymorphisms, factor V Leiden (G1691A)
and prothrombin G20210A, have been identified as risk fac-
tors for deep vein thrombosis (DVT) and pulmonary embo-
lism (PE) in Europeans and White-Americans, [11–16] but
not Black-Americans [6,17,18]. We hypothesized that the
apparent higher VTE incidence among Blacks might be due
to an increased prevalence of known VTE risk factors. To
test this hypothesis, we compared demographic and base-
line clinical characteristics from White- and Black-Ameri-
cans with objectively diagnosed VTE who were seen in one
of the seven CDC Thrombosis and Hemostasis Research
and Prevention Network centers.
Methods
Study setting, population, and design
The study setting was the seven centers (the University of Michigan
Hemophilia and Coagulation Disorders Program, Ann Arbor, MI; the
Thrombophilia Program, UNC, Chapel Hill, NC; the Michigan State Uni-
versity Comprehensive Center for Bleeding Disorders, East Lansing,
MI; the Wayne State University, Detroit, MI; the Mountain States
Regional Hemophilia and Thrombosis Center, Aurora, CO; the Duke
Hemostasis and Thrombosis Center, Durham, NC; and the New Jersey
Regional Hemophilia Program, UMDNJ-Robert Wood Johnson Univer-
sity Hospital, New Brunswick, NJ) within the CDC Thrombosis and
Hemostasis Centers Research and Prevention Network [19] with sub-
stantial numbers of Black-American patients with VTE. Patients and/or
their families attending one of the seven centers for medical care, or
seen as an inpatient consult or referral, were approached by local cen-
ter staff for study participation regardless of age, gender, or race. For
consenting patients, study participation consisted of center staff com-
pletion of a standardized data collection form for the initial and all sub-
sequent visits. In the case of pediatric patients, consent was obtained
from the parent or legal guardian as well as an assent for children older
than 7 years of age. Data were entered into a web-based registry main-
tained on a secure server within the Division of Blood Disorders at the
CDC. Patient identifying information, including name, address, physi-
cian, and insurance carrier, remained within a locally housed secure
database at each center. For purposes of confidentiality, only the study
identification number and registry information were sent to the registry
at the CDC. The registry, study protocol, and other study materials are
approved annually by the Institutional Review Boards at each of the
participating sites and at the CDC.
The registry began patient enrollment in August 2003. For this study,
the population was consenting, self-identified White- and Black-Ameri-
can adults of non-Hispanic or non-multiracial ethnicity with objectively
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diagnosed DVT and/or PE who were enrolled at one of the seven cen-
ters from August 2003 to March 2009, and for whom registry data were
available. A DVT was categorized as objectively diagnosed when symp-
toms or signs of acute DVT were present, and the diagnosis was con-
firmed by venography, compression venous duplex ultrasonography, im-
pedance plethysmography, computed tomographic venography, or mag-
netic resonance imaging. A PE was categorized as objectively
diagnosed when symptoms and/or signs of acute PE were present,
and the diagnosis was confirmed by pulmonary angiography, a ventila-
tion/perfusion lung scan interpreted as high probability for PE, com-
puted tomographic pulmonary angiography, or magnetic resonance
imaging.
Using a cross-sectional study design, we queried the CDC registry
for demographic and clinical characteristic data collected at the initial
visit for each patient age 18 years or older at enrollment and compared
these data among Whites and Blacks.
Measurements
Data collected at the initial visit included patient demographic and
clinical characteristics, referral patterns, reasons for and details of the
visit (including providers seen, concurrent medical and lifestyle condi-
tions, laboratory and radiological tests ordered, educational materials
received), diagnoses, and treatments prescribed.
Analyses
For patients with objectively diagnosed VTE, demographic, baseline,
and clinical characteristics were compared among White- and Black-
American patients, age 18 and older, both overall, and by age and gen-
der. All analyses were performed using SAS 9.2 (SAS, Institute Cary,
NC). For categorical variables of interest, univariate frequencies were
generated to calculate the prevalence and compared using Pearson’s
v2 and two-tailed P-values, and in the case of small cell sizes (5),
two-tailed Fisher’s exact P-values are reported. For continuous varia-
bles, mean values were computed and differences were tested using
Student’s t-test.
Definition of variables
The presence of medical comorbidities was defined as the patient hav-
ing the condition within the 3 months prior to the VTE event. The pres-
ence of thrombophilia was defined by diagnosis of an inherited or
acquired thrombophilia (factor V Leiden, prothrombin G20210A mutation,
antiphospholipid syndrome, antithrombin, protein C or protein S defi-
ciency) at baseline or after subsequent evaluation by a CDC Thrombosis
and Hemostasis Research and Prevention Center. For all patients with
antiphospholipid antibodies and for most patients with an inherited throm-
bophilia, the presence of thrombophilia was confirmed by laboratory test-
ing performed at a CDC Center. The updated Sapporo criteria [20] were
used for diagnosis of antiphospholipid syndrome. ‘‘Idiopathic’’ VTE was
defined as VTE in the absence of recent surgery, trauma, infection, preg-
nancy or postpartum period, oral contraceptive use or hormone therapy;
active cancer; or HIV.
To assess potential referral bias, the distance from patient residence
to Network center was compared among White- and Black-American
patients with VTE, both overall and by center. Distances represent
miles from the centroid of the home residence zip code to the centroid
of the Center’s zip code. Mean distance was calculated and then com-
pared between the groups using Student’s t-test.
Results
Of the 4,831 patients with nonbleeding disorders enrolled
in the CDC Registry from August 2003 to March 2009, 3,879
were of age 18 years or older upon enrollment and self-iden-
tified as White- or Black-American of non-Hispanic or non-
multiracial ancestry. Of these, 2,397 had at least one objec-
tively diagnosed VTE event; 2,002 were White- and 395
were Black-Americans. The distribution of White- and Black-
American VTE cases by center is shown in Table I.
The mean ± SD (range) age among Whites and Blacks
with VTE at enrollment did not differ significantly (47.7 ±
15.7 [18, 91] vs. 46.1 ± 15.6 [18, 86] years). When com-
pared with Whites, a significantly higher proportion of
Blacks were of female gender (70.6% vs. 60.6%; P 5
0.0002). The mean body mass index was higher among
Blacks (32.9 kg/m2 vs. 29.9 kg/m2; P < 0.0001).
When compared with Whites, Blacks had a significantly
lower proportion with DVT and a significantly higher propor-
tion with PE (Table II). Otherwise, the distribution of DVT
by vein location did not differ significantly by race (Table
III). The mean ± SD total number of VTE events was mar-
ginally but significantly greater among Whites (1.57 ± 1.03
vs. 1.46 ± 0.89; P 5 0.03) but did not differ significantly
among White versus Black women or men. The percentage
of Whites and Blacks with recurrent VTE also did not differ
significantly (34.9% vs. 30.7%; P 5 0.11). The mean ± SD
ages at first VTE, DVT, and PE were not significantly differ-
ent by race or by gender within race.
Among baseline characteristics previously identified as
VTE risk factors, when compared with Whites, Blacks had
a significantly lower proportion with recent surgery, trauma
or infection, and a significantly higher proportion with HIV
and sickle cell disease (Table IV). Among women, Black
women had a significantly lower proportion with recent oral
contraceptive use when compared with White women.
Among women 40 years of age, Black women had a sig-
nificantly lower proportion with recent hormone therapy.
The proportion of patients with active cancer or autoim-
mune disease did not differ by race. Among all patients
with VTE, Blacks had a significantly lower proportion with a
family history of VTE and with a diagnosed thrombophilia.
However, the lower proportion of thrombophilia among
Blacks was almost solely due to the virtual absence of the
factor V Leiden and prothrombin G20210A mutations (Table
V). The proportion with antiphospholipid syndrome and
deficiency of antithrombin, protein C, and protein S did not
differ significantly by race. Although the proportion with idio-
pathic VTE did not differ by race, Blacks had significantly
TABLE I. Distribution of Patients with Venous Thromboembolism
by Center and Race
Center White Black Total
UMDNJ-Robert Wood Johnson 199 34 233
UNC-Chapel Hill 367 56 423
Duke University Medical Center 613 240 853
Michigan State University 165 3 168
Wayne State University 21 8 29
University of Michigan, Ann Arbor 402 24 426
Mountain States Regional HTC 235 30 265
Total 2,002 395 2,397








(n 5 2,397) P-value
DVT only 1,171 (58.5) 205 (51.9) 1,376 (57.4) 0.02
PE only 288 (14.4) 109 (27.6) 397 (16.6) <0.0001
PE 1 DVT 543 (27.1) 81 (20.5) 624 (26.0) 0.006
DVT 1,714 (85.6) 286 (72.4) 2,000 (83.4) <0.0001
PE 831 (41.5) 190 (48.1) 1,021 (42.6) 0.02








(n 5 2,000) P-value
Cerebral 52 (3.0) 7 (2.5) 59 (3.0) 0.59
Retinal 26 (1.5) 3 (1.1) 29 (1.5) 0.79
Jugular 31 (1.8) 11 (3.9) 42 (2.1) 0.02
Arm 188 (11.0) 41 (14.3) 229 (11.5) 0.10
Superior vena cava 12 (0.7) 2 (0.7) 14 (0.7) 1.0
Inferior vena cava 25 (1.5) 4 (1.4) 29 (1.5) 1.0
Hepatic, portal, mesenteric 99 (5.8) 16 (5.6) 115 (5.8) 0.90
Renal 26 (1.5) 1 (0.4) 27 (1.4) 0.16
Abdomenb 138 (8.1) 23 (8.0) 161 (8.1) 1.0




Hepatic, portal, mesenteric, renal, and pelvic.
468 American Journal of Hematology
research article
lower and higher proportions of idiopathic DVT and idio-
pathic PE, respectively (Table IV).
Among other clinical characteristics, when compared with
Whites, Blacks had a significantly higher proportion with
hypertension, diabetes mellitus, and chronic renal disease
and dialysis (Table VI). The two groups did not differ signifi-
cantly regarding the proportion with stroke, cerebral palsy,
coronary artery disease/myocardial infarction, congenital
heart disease, congestive heart failure, peripheral artery
disease, or chronic liver disease.
When compared with White women, the distribution of
VTE risk factors among Black women varied significantly,
with Black women having a significantly lower proportion
with recent surgery, trauma or infection, and a significantly
higher proportion with HIV infection and sickle cell disease
(Table VII). Black women had a significantly higher propor-
tion of idiopathic PE and a significantly lower proportion of
idiopathic DVT. When compared with White men, Black
men did not differ significantly regarding recent surgery,
trauma, cancer, infection, or autoimmune disease (Table
VII); Black men did have a significantly higher proportion
with HIV infection and sickle cell disease. The proportion
with idiopathic VTE, DVT, or PE did not differ by race
among men.
Overall, the mean distance from patient residence to cen-
ter address (as reflected by ZIP code) was significantly
greater for Whites (55.0 miles, range 5 0–3,461 miles)
when compared with Blacks (31.6 miles, range 5 0–260
miles; P < 0.0001). For five of the seven centers, the mean
distance from patient residence to the center address was
significantly greater for White patients with VTE when com-
pared with Black patients with VTE and not significantly dif-
ferent for the other two centers (Table VIII). When analyzed
for distances of >30, >50, and >75 miles from patient resi-
dence to center address, the proportion by center for each
distance was either significantly greater for White patients
with VTE or not significantly different when compared with
Black patients with VTE (data not shown).
Discussion
The important findings of our study are that when com-
pared with White patients with VTE, Blacks with VTE had a
lower proportion with transient VTE risk factors (i.e., less
recent surgery, trauma and infection; and among women,
less recent oral contraceptive use and hormone therapy)
and a higher proportion with idiopathic PE. Our findings are
similar to those of the Genetic Attributes and Thrombosis
Epidemiology (GATE) study, a case–control study of risk
factors for VTE among White- and African-Americans in
which Blacks were more likely to have VTE unrelated to
cancer, or recent surgery or immobilization [6].
Our finding of an increased prevalence of idiopathic PE
among Black women is supported by previous work show-
ing a higher incidence of idiopathic PE among Blacks when
compared with Whites [8]. Given the poor survival after PE,
[21] our finding of an increased prevalence of PE among
Blacks (particularly idiopathic PE) is disturbing, especially
when coupled with previous reports of increased complica-
tions after VTE and higher PE case fatality among Blacks
[8,9,22,23].
Also similar to previous studies, [6,17,18] we found a
very low prevalence of factor V Leiden and prothrombin
G20210A carriers among Blacks with VTE. Although we
found other potential VTE risk factors such as sickle cell
trait and disease, [24] HIV-infection [25], and anticardiolipin
antibodies [26] to be higher among Blacks when compared
with Whites, the prevalence of these disorders among
Blacks was low and insufficient to account for the reported
higher VTE incidence among Blacks [5,8–10]. Blacks had a
higher BMI and a higher prevalence of hypertension, diabe-
tes mellitus, and chronic renal disease (including hemodial-
ysis), but the association of these characteristics with VTE
is uncertain [3,5,27].
Our findings do not support the hypothesis that the
higher VTE incidence among Blacks is due to an
increased prevalence of known VTE risk factors. How-
ever, we cannot exclude the possibility of as yet unidenti-
fied environmental and/or social risks factors in the etiol-
ogy of VTE among Black-Americans. For many prevalent
health conditions, Black-Americans suffer a disproportion-
ate burden of disease including higher incidence, morbid-
ity, and mortality when compared with White-Americans
[28]. The higher prevalence of PE among Black-American
women in our study may reflect health disparities in VTE
as well, including the social factors of access to care
and delayed identification of DVT. Alternatively, the biol-
ogy of VTE among Blacks may increase the proportion






(n 5 395) Total P-value
Postsurgery 226 (11.3) 22 (5.6) 248 (10.4) 0.0006
Trauma 109 (5.4) 8 (2.0) 117 (4.9) 0.006
Cancer 216 (10.8) 45 (11.4) 261 (10.9) 0.73
Infection 51 (2.6) 2 (0.5) 53 (2.2) 0.01
HIV infection 2 (0.1) 10 (2.5) 12 (0.5) <0.0001
Sickle cell disease 0 12 (3.0) 12 (0.5) <0.0001
Autoimmune diseasea 299 (14.9) 60 (15.2) 359 (15.0) 0.90
Oral contraceptive useb 156 (12.9) 17 (6.1) 173 (11.6) 0.002
Hormone therapyb 35 (2.9) 2 (0.7) 37 (2.5) 0.03
Thrombophiliac 604 (30.2) 56 (14.2) 660 (27.5) <0.0001
Family history of VTE 240 (12.0) 22 (5.6) 262 (10.9) 0.0002
Idiopathic VTE 1,381 (69.0) 272 (68.9) 1,653 (69.0) 0.96
Idiopathic DVT 1,188 (59.3) 196 (49.6) 1,390 (58.0) 0.003
Idiopathic PE 580 (29.0) 135 (34.2) 715 (29.8) 0.04
a
Autoimmune disease includes patients with systemic lupus erythematosus,
rheumatoid arthritis, inflammatory bowel disease, and hypothyroidism.
b
Among women only (n 5 1,214 White, 279 Black).
c
Thrombophilia includes factor V Leiden or prothrombin G20210A mutations,
deficiency of antithrombin, protein C or protein S, or antiphospholipid syndrome.








(n 5 2,397) P-value
Antithrombin deficiency 15 (0.8) 3 (0.8) 18 (0.8) 1.0
Protein C deficiency 29 (1.5) 6 (1.5) 35 (1.5) 0.92
Protein S deficiency 50 (2.5) 15 (3.8) 65 (2.7) 0.15
Factor V Leiden 293 (14.7) 6 (1.5) 299 (12.5) <0.0001
Prothrombin G20210A 72 (3.6) 1 (0.3) 73 (3.1) 0.0004
Antiphospholipid syndrome 213 (10.6) 32 (8.1) 245 (10.2) 0.13







(n 5 2,397) P-value
Stroke 104 (5.2) 25 (6.3) 129 (5.4) 0.36
Cerebral palsy 2 (0.1) 0 2 (0.1) 1.0
Coronary artery disease 97 (4.9) 24 (6.1) 121 (5.1) 0.31
Congenital heart disease 14 (0.7) 4 (1.0) 18 (0.8) 0.52
Prosthetic heart valve 8 (0.4) 7 (1.8) 15 (0.6) 0.006
Congestive heart failure 26 (1.3) 8 (2.0) 34 (1.4) 0.26
Peripheral artery disease 26 (1.3) 5 (1.3) 31 (1.3) 1.0
Hypertension 398 (19.9) 150 (38.0) 548 (22.9) <0.0001
Hyperlipidemia 282 (14.1) 50 (12.7) 332 (13.9) 0.45
Diabetes mellitus 136 (6.8) 54 (13.7) 190 (7.9) <0.0001
Liver disease 22 (1.1) 8 (2.0) 30 (1.3) 0.14
Renal disease 71 (3.6) 30 (7.6) 101 (4.2) 0.0003
Dialysis 14 (0.7) 10 (2.5) 24 (1.0) 0.003
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of VTE events that present clinically as PE when com-
pared with Whites.
Despite the rarity of known genetic risk factors among
Black-Americans, [29–34] our findings suggest that a
genetic component may exist in the etiology of VTE among
Blacks. In support of this hypothesis, the plasma levels of
several procoagulant and anticoagulant factors both vary by
race [35–38] and exhibit substantial heritability [39–43].
When compared with Whites, Blacks have higher levels of
fibrinogen, [35,36,38] factor VIII, [37,38,44] von Willebrand
factor [37,38,44], and plasma fibrin D-dimer [38,45,46], and
lower levels of protein C [36]. Moreover, among Blacks,
VTE has been associated with increased levels of fibrino-
gen, [29] factor VIII [47], and plasma fibrin D-dimer [48].
Although the lower prevalence of a family history of VTE
among Blacks when compared with Whites might argue
against a heritable component, this observation could also
be explained by the frequent incomplete penetrance of
inherited thrombophilia [14,49–51].
Our study has important limitations. As there was no
control group, we cannot test the characteristics measured
in this study as potential VTE risk factors by race. More-
over, as our study was not population based, our findings
may not represent the full spectrum of VTE disease occur-
ring in the community. For example, because patients had
to live sufficiently long to reach a center, rapidly fatal VTE
(and especially fatal PE) cases are under represented as
are patients with VTE in chronic care facilities. In addition,
each of the seven centers did not contribute equally to the
study population. Thus, the findings may be skewed by the
one or possibly two centers contributing the most patients
to the registry. Finally, we cannot exclude referral bias. In
fact, the characteristics of the two racial groups in this
study likely do not reflect those of the community. When
compared with the population-based studies of predomi-
nantly Whites of non-Hispanic ancestry, Whites in this study
were younger and had a lower proportion with recent sur-
gery (11.3% vs. 23.8%), active cancer (10.8% vs. 18.9%),
and trauma (5.4% vs. 12%), [3] and a higher proportion
with oral contraceptive use (12.9% vs. 8.1%; Barsoum
et al., submitted) and idiopathic VTE (72.8% vs. <25%
[52]) The mean age of Blacks at first VTE in this study
(41.5 years) was also lower when compared with the age
of Black patients with VTE in the GATE study (47.5 years;
Ref. 6) and the 1996 California Patient Discharge Data Set
(58 years; Ref. 8), suggesting potential referral bias among
Blacks in our study as well. However, at least based on the
distance from patient residence to Center address, there is
no reason to expect that referral bias was greater among
Blacks when compared with Whites. Although inability of
Blacks to travel similar distances as Whites could also
account for this observation, such an explanation would
make Blacks less likely to be referred compared to Whites.
Conclusions
Despite these limitations, the prevalence of common
transient or acquired risk factors (i.e., recent surgery,
trauma, infection) appears to be lower among African-
American patients with VTE, while the prevalence of idio-
pathic VTE (especially idiopathic PE) appears to be higher.
We believe these findings support the hypothesis that herit-
ability plays a significant role in the etiology of VTE among
Black-Americans. As the carrier frequencies of the two
most common inherited polymorphisms associated with
VTE (i.e., factor V Leiden, prothrombin G20210A) are
extremely low among Black-Americans, we also hypothe-
size that other as yet unrecognized inherited polymor-
phisms are associated with VTE in blacks. Such polymor-
phisms could give important insights into as yet unrecog-
nized pathways that are associated with VTE.
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